Evaluating the CellSearch CMMC Assay for Non-Invasive Longitudinal MRD Monitoring
This study demonstrates that the CellSearch CMMC assay is a highly sensitive, analytically validated liquid biopsy platform capable of non-invasive, longitudinal minimal residual disease monitoring in multiple myeloma, offering a patient-friendly alternative to reduce the reliance on invasive bone marrow biopsies.